MassBio – Biosimilars – Our View

June 16, 2011

Drugs developed through biotechnology differ from traditional small molecule chemical drugs. They are “biologics” that are complex medicines manufactured using living organisms. Biosimilars, also known as follow-on biologics are products that are similar to, but not the same as, an innovative new drug. They are not generic drugs, which are products shown to be the […]

Read More


MOBIO Applauds Formation of Missouris Legislative Biotech Caucus

June 16, 2011

A bipartisan group of 29 Missouri state legislators has announced its intention to form a state biotechnology caucus. Led by Kansas City Reps. Ryan Silvey (R-38) and Mike Talboy (D-37), caucus members will use this forum to continue to explore the state’s deep biotech base of assets and consider market factors that affect Missouri’s bioscience […]

Read More


Missouri Biotechnology Association E-newsletter – MOBIO Progress

June 16, 2011

MOBIO Progress is the Missouri Biotechnology Association’s electronic newsletter with news and information to promote scientific advancement for a better Missouri. Read More

Read More


AZBio Resource Network

June 16, 2011

July 8, 2011 SkySong – Room 249- Imagination – 1475 N. Scottsdale Road, Suite 200 Scottsdale, AZ Read More

Read More


AZBio Government Affairs Committee Meeting

June 16, 2011

June 9, 2011 SkySong – 1475 N. Scottsdale Road, Suite 200 Scottsdale, AZ Read More

Read More


Catalyst for Growth – AZ Bio moves forward with new CEO and an aggressive agenda

June 16, 2011

The Arizona BioIndustry Association, the unified voice of Arizona’s growing bioscience industry, today announced the hiring of Joan Koerber-Walker who joins the state-wide organization as President and CEO of AZBio effective immediately. Read More

Read More


Oregon Bioscience Association

June 16, 2011

Calendar of Events 2011 Read More

Read More


FDA must use caution with biosimilars

April 14, 2011

William P. Bro, Kidney Cancer Association At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney […]

Read More


Drugmakers could take hit under Obama budget

February 16, 2011

Obtaining approval of new drugs can take as much money as $1 billion by the time research, manufacturing, safety and clinical trials have concluded. The pharmaceutical company patents the drug as soon as it is made, usually very early in the process of drug development. The patent protects that drug from being copied by anyone […]

Read More